Altimmune Inc (ALT)
NASDAQ:ALT
ALT Stock Chart & Stats
$3.24
$0.16(2.19%)
At close: 4:00 PM EST
$3.24
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.87 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.35M
Market Cap
$421.43M
Enterprise Value$277.88M
Total Cash (Recent Filing)$273.46M
Total Debt (Recent Filing)$35.69M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding130,069,980
10 Day Avg. Volume2,199,004
30 Day Avg. Volume3,352,253
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue6.78K
Enterprise Value/Gross Profit-18.63
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$13.50Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$5.60K
Bulls Say, Bears Say
Bulls Say
Expansion Into Alcohol-related IndicationsProgress in alcohol use disorder and alcohol-associated liver disease programs could open new development and commercial opportunities beyond the core liver disease indication.
Mechanism Of Action DifferentiationDual mechanism combining GLP-1 appetite suppression with glucagon-driven liver fat reduction may provide superior clinical effects versus GLP-1-only drugs, supporting a differentiated therapeutic profile.
Regulatory Pathway ClarityRegulatory alignment on key Phase III parameters together with Breakthrough Therapy Designation improves the clarity of the approval pathway and lowers late-stage development uncertainty.
Bears Say
Clinical Differentiation ConcernsPhase IIb data showed therapeutic activity but did not establish clear clinical differentiation from existing treatments, challenging prospects for premium adoption.
Competitive Market PressureA crowded MASH treatment market with established products and multiple emerging competitors raises the bar for commercial success and may limit market share and pricing power.
Development And Financing RiskMaterial clinical, regulatory, and financing risks create significant uncertainty that could prevent the drug from reaching the market or meeting current valuation assumptions.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.87 and its highest was $7.73 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $421.43M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is May 19, 2026 which is in 36 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Mar 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.234 by -$0.036.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.24.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 130,069,980 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.234. Following the earnings report the stock price went down -17.916%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (316.67% Upside)
$13.50 (316.67% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $198.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.11%
12-Months-Change
Fundamentals
Return on Equity
-49.35%
Trailing 12-Months
Asset Growth
100.95%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by robust Phase II clinical data (early NASH resolution, antifibrotic signals, 7.5% weight loss at 48 weeks), favorable tolerability, FDA Breakthrough designation, clear alignment with the FDA on Phase III design, completed AUD enrollment, and a strengthened balance sheet with a pro forma cash position (~$340M) providing runway into 2028. Key risks discussed included increased near-term operating expenses and G&A, a widened net loss, reliance on biopsy-driven endpoints (NITs not yet registrational), operational and enrollment execution risks for a large global Phase III, and competitive dynamics in the dual-agonist space. On balance, the positives (clinical differentiation, regulatory progress, funding runway, commercial interest) outweigh the challenges, though execution and funding discipline will be critical as Phase III is initiated.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$13.50
▲(316.67% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.65% Insiders
9.45% Mutual Funds
5.75% Other Institutional Investors
72.95% Public Companies and Individual Investors